XTX Topco Ltd Has $231,000 Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

XTX Topco Ltd boosted its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 42.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,560 shares of the company’s stock after buying an additional 8,801 shares during the quarter. XTX Topco Ltd’s holdings in GoodRx were worth $231,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Beacon Capital Management LLC bought a new position in GoodRx in the first quarter valued at about $28,000. Plato Investment Management Ltd bought a new position in GoodRx in the second quarter valued at about $43,000. Gerber LLC bought a new position in GoodRx in the fourth quarter valued at about $75,000. EntryPoint Capital LLC raised its position in GoodRx by 165.2% in the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after purchasing an additional 11,548 shares during the last quarter. Finally, Syon Capital LLC bought a new position in GoodRx in the fourth quarter valued at about $168,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Trading Up 2.2 %

Shares of GDRX stock opened at $6.85 on Friday. The company has a market cap of $2.60 billion, a P/E ratio of -684.32, a PEG ratio of 3.38 and a beta of 1.38. The stock has a 50 day simple moving average of $7.81 and a two-hundred day simple moving average of $7.57. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. During the same quarter in the previous year, the firm posted $0.02 earnings per share. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. Research analysts forecast that GoodRx Holdings, Inc. will post 0.14 earnings per share for the current year.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. UBS Group dropped their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Morgan Stanley increased their target price on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research report on Monday, June 10th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a research report on Friday, August 9th. Finally, Citigroup lowered their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.36.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.